A generic drug is an exact chemical copy of a brand-name pill. A biosimilar is not an exact copy of anything. It is a biologic medicine, made in living cells, that the FDA has found to be highly similar to an already-approved biologic, with no meaningful differences in safety, purity or potency. That gap between "identical" and "highly similar" drives every regulatory and pharmacy difference between the two categories.
The distinction matters for anyone reading a pipeline, a payer policy or a pharmacy benefit. Generic substitution is largely automatic. Biosimilar substitution is not, because the FDA treats the two products as related but distinct, and only a subset of biosimilars carries the "interchangeable" designation that lets a pharmacist swap them without the prescriber's sign-off. Per FDA's biosimilars resource, these products serve conditions from psoriasis and arthritis to kidney conditions and cancer, and the agency maintains separate approval and education tracks for biosimilars and interchangeables.
Why can't a biologic be copied exactly?
A small-molecule drug is a defined chemical. Manufacturers can synthesize the same compound, atom for atom, from a written recipe. Two batches made years apart in different plants should be chemically indistinguishable, which is what makes a generic possible.
Biologics are different. They are large proteins, or related products, grown in living cells. According to Wikipedia's overview of biosimilars, these products exhibit high molecular complexity and can be sensitive to changes in the manufacturing process. The final characteristics of a recombinant therapeutic protein depend heavily on choices made during production: the cell line used, the culture conditions, the purification steps and the formulation. Change any of those, and the product's sugar structures, folding or impurity profile can shift in ways an analytical test may not fully capture.
This is why the biosimilar pathway exists at all. No manufacturer can demonstrate that a biologic copy is identical, so regulators built a framework around demonstrating that it is close enough.
What does FDA actually require for approval?
The evidentiary package for a biosimilar is layered. Per FDA's guidance as summarized by Wikipedia, an applicant must show through analytical studies that the product is highly similar to the reference product, despite minor differences in clinically inactive components. Animal toxicity data, human pharmacokinetic and pharmacodynamic data, and clinical data including immunogenicity assessments round out the file.
That is more testing than a generic faces. A generic relies on bioequivalence studies showing the same exposure in the body. A biosimilar applicant must characterize a large, variable molecule and then run clinical work to confirm that the analytical differences do not matter. The American Cancer Society notes that because biosimilars are not exact copies, they go through more testing than generic drugs, with each one tested in clinical trials comparing it to the original biologic.
The FDA's first biosimilar approval under this framework came in March 2015, when the agency licensed Sandoz's Zarxio, a filgrastim product biosimilar to Amgen's Neupogen. Notably, FDA approved Zarxio as a biosimilar, not as an interchangeable product, and said so explicitly at the time.
What is the comparability exercise?
The scientific core of a biosimilar application is often called a comparability exercise. The applicant runs a battery of structural and functional tests on its product and on the reference biologic, side by side. The goal is a head-to-head analytical dossier: same primary sequence, comparable higher-order structure, comparable biological activity, comparable impurity and stability profiles.
Where analytical results match closely, the applicant can argue that fewer clinical studies are needed. Where gaps appear, regulators can require more clinical work. The exercise is iterative, and the amount of clinical data varies product by product. This is a structural difference from the generic world, where the analytical question is simpler and the clinical question reduces to exposure.
Manufacturers also have to keep the product consistent over its lifecycle. Wikipedia's entry notes that all biopharmaceuticals, biosimilars included, must maintain consistent quality and clinical performance throughout their lifecycle, which for a living-cell process means ongoing process control rather than a fixed chemical formula.
How does extrapolation of indications work?
A generic inherits every approved indication of its reference drug, because identity is identity in every use. A biosimilar does not automatically run clinical trials in every indication its reference product holds. Instead, FDA can extrapolate. Readers following this should also see FDA's Expedited IND Comment Window Nears Close After Gene Therapy Holds.
The logic runs like this. If the biosimilar is highly similar analytically, and clinical data confirm similar pharmacokinetics, safety and immunogenicity in at least one sensitive condition of use, the agency may license the biosimilar for other conditions of use for which the reference product is licensed, without separate trials in each. Wikipedia's summary of the framework describes this as demonstrating safety, purity and potency in one or more appropriate conditions of use.
Extrapolation is why a single biosimilar can carry the full label of a reference monoclonal antibody across autoimmune and oncology indications despite being studied clinically in only some of them. It is a regulatory judgment built on the totality of the comparability data, not a shortcut the applicant takes unilaterally.
Why are substitution rules different?
This is where the practical difference shows up at the pharmacy counter. A pharmacist can usually fill a generic in place of the brand-name drug without calling the prescriber. Biosimilars work differently. Per Cleveland Clinic's patient explainer, substitution depends on whether FDA has designated the biosimilar as interchangeable. An interchangeable biosimilar can be substituted for its reference biologic without the prescriber's approval. A non-interchangeable biosimilar requires the prescriber to approve the switch, and the doctor may decline.
The interchangeable designation requires additional testing beyond biosimilarity, work designed to show that switching between the products produces the same clinical result. The American Cancer Society describes this as extra testing a biosimilar must go through after approval before it is considered interchangeable.
The legal basis sits in the Biologics Price Competition and Innovation Act of 2009, the law that gave FDA authority to approve both biosimilars and interchangeables. Under that statute, only a product licensed as interchangeable may be substituted for the reference product without the intervention of the prescribing health care provider.
Our analysis: the substitution distinction is the single clearest marker that biosimilars and generics are separate regulatory categories, not two names for the same idea. The pharmacy rules follow directly from the science. Exact copies allow automatic substitution; near copies require a designation earned through switch-specific evidence.
What does the market look like?
The biosimilar category has matured into a real commercial segment. Cleveland Clinic lists biosimilars on the market for widely used biologics including adalimumab (Humira), trastuzumab (Herceptin), rituximab (Rituxan), infliximab (Remicade), pegfilgrastim (Neulasta) and insulin glargine (Lantus), among others. Some biologics carry a dozen or more approved biosimilars; ustekinumab (Stelara) alone has eight listed biosimilar products.
Cost is the driver. The American Cancer Society reports that biosimilars typically cost 10% to 50% less than their brand-name biologics, and that the Biologics Price Competition and Innovation Act created the faster approval pathway that made them possible. Not every biologic has a biosimilar yet, and insulin products only opened to biosimilar competition in the United States in March 2020, when most protein products previously approved as drug products transitioned into the biologics framework.
Interchangeability is arriving product by product. Truxima, the Celltrion and Teva rituximab product, became the first interchangeable rituximab biosimilar in the United States, a milestone covered in Dark Biotechnology's report on the designation. Each new interchangeable widens the set of switches a pharmacy can make on its own authority. We covered a connected angle in Celltrion and Teva's Truxima Becomes First Interchangeable Rituximab Biosimilar in the US.
What should a reader take away?
The two categories answer different questions. A generic asks: is this the same molecule? A biosimilar asks: is this molecule close enough, in every way that matters clinically, to the reference biologic? The first question has a binary answer. The second requires analytical characterization, clinical confirmation and, for substitution, a separate interchangeable showing.
For industry readers, the practical consequences run through development cost, approval timelines and commercial strategy. Biosimilar programs carry more clinical burden than generic programs. Extrapolation can expand the label without new trials, but only on the strength of the comparability file. And market access turns on the interchangeable designation in a way no generic ever faces. The evidence base for all of it is public: FDA's biosimilars hub, the registry entries behind each approval, and the disclosures of the companies running the programs. What remains unsettled is pace. How quickly interchangeability spreads across the remaining reference biologics, and how payers handle non-interchangeable products, will shape the category's next several years.
